• Aucun résultat trouvé

New aspects in the treatment of multiple sclerosis with interferon beta-1b

N/A
N/A
Protected

Academic year: 2021

Partager "New aspects in the treatment of multiple sclerosis with interferon beta-1b"

Copied!
1
0
0

Texte intégral

(1)

J Neurol (2004) 251 [Suppl 4] : IV/1 DOI 10.1007/s00415-004-1401-4

Ludwig Kappos

New aspects in the treatment of multiple

sclerosis with interferon beta-1b

Introduction

In the decade since the first approval of interferon beta-1b (Betaferon®) for relapsing-remitting (RR) multiple sclerosis (MS), considerable progress has been made in understanding the pathological mechanisms underly-ing MS and developunderly-ing strategies to maximise the effi-cacy of existing therapies. The papers presented in this supplement represent much of the current thinking in the field of MS, as presented at a 1-day meeting in Vienna in March 2002. The purpose of the meeting, entitled New Aspects in the Treatment of Multiple Sclerosis with Betaferon®, was to discuss the current status of MS re-search and treatment and highlight some of the existing challenges for future MS diagnosis and disease manage-ment.

The present thinking on the pathogenetic mecha-nisms responsible for tissue damage is outlined, as are

the latest developments in magnetic resonance imaging (MRI) techniques. The development of new MRI tech-niques addresses the need for better, more clinically rel-evant outcome measures, and has already increased our understanding of MS pathology and improved diagno-sis. In terms of treatment, the data suggesting that treat-ing patients after the first clinical event (clinically iso-lated syndrome) can produce some benefit are reviewed, as are outstanding questions, such as the long-term effects of early treatment, and early high-dose fre-quent interferon beta therapy – questions that are to be addressed by the BENEFIT (BEtaferon in Newly Emerg-ing multiple sclerosis For Initial Treatment) study. Fi-nally, the important role of neurorehabilitation and its effects on quality of life are discussed.

While there are still many unanswered questions in MS therapy, the progress to date gives cause for opti-mism that current basic research and clinical trials will provide greater benefits for patients in the future.

JON 1401

Professor Ludwig Kappos ()

Outpatient Clinic Neurology-Neurosurgery University Hospitals Kantonsspital Petersgraben 4 4031 Basel, Switzerland Tel.: +41-61/265-4193 Fax: +41-61/265-4100 E-Mail: lkappos@uhbs.ch

Références

Documents relatifs

Changes in Gene Expression and Estrogen 424 Receptor Cistrome in Mouse Liver Upon Acute E2 Treatment, Mol Endocrinol. Effects of various 426 selective estrogen receptor

Donc, la source dont l’auteur a fait allusion dans le texte est une source de

The originality of a non-persuasive conception is to shake the following idea that, in either an implicit or explicit way, subtends the majority of other theories: the

Et court tant haut dans la plaine du ciel Et tant me montre les diamants du soleil Et tant toujours me caresse la peau Et tant toujours me chante dans les os Que je deviens un

Lecture : 21 % des femmes connaissent au moins un changement de situation professionnelle dans la continuité d’une période d’emploi sur la période ; c’est le cas de 27 % de

Thirteen different non-critical care journals published the 45 classic critical care articles; the New England Journal of Medicine leads this list with 11 such articles, followed

[r]

Deletion of residues 98 to 121 of Ego1 does not affect the vacuolar membrane location of Ego1 nor the subsequent vacuolar recruitment of the other EGOC components.. (A) Ego1